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Abstract
Staphylococcus aureus has maintained its clinical relevance as a major cause

of hospital and community acquired infections globally with a high burden of
antimicrobial resistance (AMR). Though reported, the burden of infection,
antimicrobial resistance and molecular epidemiology of S. aureus are not well
defined in Kenya. This descriptive review evaluated reported data on the detection and characterization of S. aureus infections in Kenya. Published data
between 2000 and 2020 were evaluated. S. aureus isolation frequencies varied
from 1% in blood specimens to 52.6% among skin and soft tissues infections
while MRSA rates ranged from 1% to 84.1%. While penicillin resistance has
consistently been high, last line and recent antibiotics such as vancomycin,
linezolid, teicoplanin and daptomycin have retained their efficacy. Data on
MRSA carriage in the community, among HCWs and inpatients is limited.
Global clones (CC1, CC5, CC8, CC22, CC30, CC45 and CC239) alongside a
few novel MRSA strains have been reported with staphylococcal protein A
(spa) sequence based clustering yielding four major clusters (spa CC359, spa
CC005, spa CC121 and spa CC021) in circulation. MRSA strain ST239/241
(t037) seems predominant in the country. Despite a clear paucity of data, the
present analysis points to a high infection and AMR burden in S. aureus with
global MRSA clones in circulation. Standardized national surveillance and
reporting incorporating molecular tools for identification and characterization will help fill existing gaps in the understanding of the evolving epidemiology of MRSA infections.
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1. Introduction
Staphylococcus aureus is one of the most frequently encountered pathogens in
clinical settings as a cause of a wide range of infections of varying severity which
include boils, cellulitis, food poisoning, sepsis, osteomyelitis, pneumonia and
endocarditis [1]. Evolution and spread of antimicrobial resistance present a major challenge in the control of infections associated with the pathogen. Methicillin resistant S. aureus (MRSA) strains are especially troublesome as they may be
associated with increased morbidity, a heightened risk of mortality, longer hospital stays and higher healthcare costs [2].
The first WHO report on global AMR surveillance identified MRSA prevalence of at least 50% in five of the six WHO regions [2]. Some MRSA strains
have emerged as sources of infections in apparently healthy individuals in the
community, a clear departure from their traditional association with healthcare
settings among high risk patient populations [3]. The ever growing resistance
coupled with a declining pipeline of new antimicrobials and a lack of an effective
anti-staphylococcal vaccine necessitate concerted efforts in AMR surveillance,
drug and vaccine discovery [4].
Staphylococcal infections and associated antimicrobial resistance have been
reported in different settings in Africa in spite of disparities within and between
countries [5] [6]. However, the WHO report on global AMR surveillance identified a lack of adequate data from the WHO Africa region as a major challenge in
the estimation of the burden of AMR. A recent analysis of the clinical and economic burden of AMR in developing countries found a lack of sufficient data
from Africa to warrant any analyses [7]. Moreover, there is limited data on the
molecular epidemiology of drug-resistant S. aureus infections in Africa with inadequate technical capacity, high costs and complexity of existing molecular
tools cited as challenges [8] [9].
To contribute towards filling the current gaps in the epidemiology of S. aureus
infections in Kenya, we have reviewed 20-year published data with respect to S.
aureus isolation frequencies, antimicrobial resistance profiles and molecular epidemiology. Further, we offer perspectives for future surveillance approaches and
reporting of AMR in this pathogen.

2. Methods
2.1. Literature Search
Between 15th and 30th May, 2020, the authors searched different databases (African Journals OnLine (AJOL), Scopus, MEDLINE, EBSCOhost and ISI Web of
knowledge) for published literature on S. aureus infections in Kenya using the
DOI: 10.4236/ojmm.2020.104018
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following key words: “Staphylococcus aureus”, “prevalence”, “antimicrobial resistance”, “molecular epidemiology”, “Kenya”. The criteria for inclusion were:
Studies reporting data from Kenya; published in English, reporting on isolates
between the year 2000 and 2020, focusing on clinical S. aureus infections and
based on a minimum of 30 non-duplicate isolates. A hand search was conducted
on the bibliographic references of individual publications to identify any additional references. Further, grey literature was searched for relevant data. Abstracts of studies meeting the inclusion criteria were assessed for relevance before selection of the final dataset. Where data was lacking in the publication, attempts were made to contact the authors. In the end 18 publications were included.

2.2. Clustering of Spa Types
More recently, it has been suggested that spa typing combined with clustering
using the based upon repeat pattern (BURP) algorithm yields results of comparable discrimination with those of multilocus sequence typing (MLST) and its
associated clustering algorithm, based upon related sequence type (BURST) but
with advantages of reduced costs and turnaround times [10]. As such, we retrieved sequences of all reported spa types using their repeat succession from

SpaServer database (https://spa.ridom.de/index.shtml) and clustered them based
on the BURP algorithm [11] using the Ridom StaphType Software (Ridom Bioinformatics). The clustering was based on the “exclude spa types with <5 repeats
and cluster sequences if cost ≤ 4” parameters [11]. A total of 194 sequences classified into 61 spa types were evaluated. The spa types were distributed across
four regions of Kenya namely: Nairobi (71), Thika (85), Kericho (18) and Kisumu (20).

3. Results
3.1. Prevalence of S. aureus Infections
A majority of Kenyan studies reporting on the occurrence of S. aureus infections
are from public and private health facilities in the capital city of Nairobi. The
earliest report is by Ladhani and colleagues in the coastal county of Kilifi where
bacteremia due to S. aureus among children aged between 1 and 12 years was
observed in 5% (106/2100) of all positive blood culture isolates between 1996
and 2001 [12]. MRSA rate was 1% of all S. aureus isolates. Most of these infections were community acquired with malnutrition, younger age and absence of a
focus of infection identified as significant risk factors for mortality which was at
the time estimated at 24% [12].
Kohli and colleagues conducted a five-year (2003-2008) retrospective analysis
of records of 18,750 blood culture specimens in a private university hospital in
Nairobi. A total of 1092 (5.8%) blood stream bacterial pathogens were identified
where S. aureus was the most frequently detected at 2% (368/18,750) [13]. In
what may be regarded as the first report from a multi-center study, Maina et al.
DOI: 10.4236/ojmm.2020.104018
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detected S. aureus in 45.8% (82/179) of specimens from skin and soft tissue infections from five centers within Nairobi (2 public hospitals, 2 private hospitals
and 1 research institute) between 2005-2007 [14].
At the Moi Teaching and Referral Hospital (MTRH), Kenya’s second largest
national referral facility, Akoru and others recovered 107 S. aureus between 2010
and 2011 among clinical samples in nine departments including outpatient, ICU,
pediatric, burn and surgical units. This study did not report on the isolation rate
of S. aureus [15]. Rutare reported a S. aureus detection rate of 32.6% in 218 swab
and tracheal aspirate specimens among pediatric ICU patients at Kenyatta National Hospital in 2012 [16] while Kanaga identified S. aureus as the most common cause of wound infections at 52.6% (79/150) among pediatric surgical patients in the same hospital in 2014 [17]. Maina et al. observed S. aureus as a
leading cause of community onset infections (16% of all Blood Stream Infections
isolates) in bacteremia cases based on four-year retrospective analysis of laboratory records at Aga Khan University Hospital [18].
Aiken et al. reported S. aureus in 8.9% of 950 screens (733 inpatients) collected by means of repeated cross-sectional surveys in Thika Level 5 Hospital
[19]. This remains the largest study evaluating carriage of MRSA among inpatients in a healthcare facility in Kenya. Nyasinga et al. detected S. aureus in 24.4%
(54/221) of specimens collected mainly from skin and soft tissue infections in a
surveillance study covering Nairobi, Kericho and Kisumu counties between 2015
and 2016. Over 87% of the isolates were associated with community acquired
infections [9].
Reports of carriage of S. aureus and MRSA among healthcare workers (HCWs)
in Kenya are limited. Omuse and colleagues screened 246 HCWs in a tertiary
private health facility in Nairobi and isolated S. aureus in 18.3% (45/246) of
them. No MRSA was isolated in the study [20]. Mogere et al. analyzed 180 nasal
and hand screens at Kenyatta National Hospital and identified S. aureus in
34.4% (62/180) of HCWs out of which 59.7% (37/62) were MRSA (Table 1) [21].

3.2. Antimicrobial Resistance Patterns in S. aureus
Different investigators used both manual and automated antimicrobial susceptibility testing (AST) platforms and in total AST results for 32 drugs were reported. However, for purposes of comparisons, only 11 drugs were considered as
others were reported in very few studies or belonged to the same drug class. The
highest proportion of MRSA was reported by Maina et al. in 84.1% of isolates
from skin and soft tissue infections from five facilities within Nairobi [14]. At
the Moi Teaching and Referral Hospital, Akoru et al. reported a MRSA frequency of 36.5% (39/107) [15]. In the same study, isolates showed > 90% resistance
against erythromycin, tetracycline and rifampicin even though it is worth noting
that the investigators focused on MRSA strains which are generally associated
with multidrug resistance.
Kohli et al. reported a MRSA detection rate of 21% among blood stream isolates in a private hospital between 2003 and 2008 [13]. An MRSA rate of 6% and
DOI: 10.4236/ojmm.2020.104018
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Table 1. A summary of reported studies on Staphylococcus aureus infections in Kenya.
Year

Location

Facility

Population

Sample
size

Study design

Specimen type

S. aureus
detection

MRSA
detection

Reference

1996-01

Kilifi

Public

Children

2100

Retrospective

Blood

5% (106/2100)

1% (1/106)

[12]

2003-08

Nairobi

Private

All age

18750

Retrospective

Blood

2% (368/18750)

21% (76/364)

[13]

2005-07

Nairobi

Public
& private

All age

179

Prospective,
multicenter

SSTIs

45.8% (82/179)

84.1% (69/82)

[14]

2010

Nairobi

Private

HCWs

246

Prospective

Nasal swabs

18.3% (45/246)

0

[20]

2011

Thika

Public

All age

733

Prospective
cross-sectional

Carriage swabs

10% (74/733)

7% (6/86)

[19]

2012

Nairobi

Public

Pediatric ICU

218

Prospective

Swabs &
tracheal
aspirates

32.6% (71/218)

46.5% (33/71)

[16]

2011-13

Nairobi

Private

All age

NR

Retrospective

Heterogeneous

NR (n = 731)

3.7% (27/731)

[22]

2014

Nairobi

Public

Pediatric/
Surgical

150

Prospective

Wounds

52.6%
(79/150)

50.6% (40/79)

[17]

2014-16

Nairobi

Public

All age

NR

Retrospective

Heterogeneous

NR (n = 944)

27.8% (232/831)

[23]

2014-16

Nairobi

Public

Adults

187

Hybrid

Heterogeneous

NR

53.4% (100/187)

[24]

2010-11

Rift valley

Public

All age

NR

Retrospective

Heterogeneous

NR (n = 107)

36.5% (39/107)

[15]

2015

Nairobi

Public

HCWs

180

Prospective

Nasal &
hands swabs

34.4% (62/180)

59.7%
37/62

[21]

2015-16

Nairobi,
Kisumu &
Kericho

Public

All age

221

Prospective

Heterogeneous

24.4% (54/221)

11%
(6/54)

[9]

HCWs-Healthcare workers; ICU-Intensive Care Unit; NR-Not reported; SSTIs-skin and soft tissue infections.

resistance of 16% and 13% against tetracycline and erythromycin respectively
were reported among isolates from a private facility in Nairobi in 2014. In the
same study, vancomycin and linezolid showed the highest effectiveness [18].
The lowest proportion of MRSA in Kenya was reported by Omuse and colleagues who detected MRSA strains in 3.7% of 731 isolates from two private
health facilities in Nairobi. Increased susceptibility was seen for vancomycin,
teicoplanin and linezolid while 92% of the isolates were resistant to penicillin
[22]. Aiken et al. showed a low MRSA detection of 7% among inpatient carriage
isolates in a public hospital outside of Nairobi while Nyasinga et al. reported an
MRSA rate of 11% among isolates from three counties in Kenya [9].
Gitau et al. analyzed 944 isolates collected between 2014 and 2016 at the Kenyatta National Hospital and reported an MRSA rate of 27.8% (262/944) (Table
2). Marked resistance against penicillin (92%) and moderate resistance against
trimethoprim/sulfamethoxazole (56.9%) and tetracycline (33.2%) were reported.
High susceptibilities to quinupristin/dalfopristin, linezolid, teicoplanin and vancomycin were observed (95% - 100%) [23].
An evaluation of resistance profiles of isolates from the internal medicine department of Kenyatta National Hospital between 2014 and 2016 revealed an
DOI: 10.4236/ojmm.2020.104018
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Table 2. Antimicrobial resistance profiles of Staphylococcus aureus from different studies.
Drug
Study

OXA/FOX PEN

TET TMP/SXT ERY

CLN GEN

[13]
(n = 364)

21%

[19]
(n = 86)

7%

[14]
(n = 82)

84.1%

NR

NR

75.6%

[16]
(n = 71)

46.5%

NR

29.6%

[22]
(n = 731)

3.7%

92.2% 15.5%

[15]
(n = 39)*

36.5%

NR

92%

NR

92%

87%

[23]
(n = 944)

28%

92%

33%

57%

26%

[21]
(n = 62)

18.9%

46.8%

[9]
(n = 52)

11%

98%

67%

[25]
(n = 32)

21%

100% 34.3%

NR

NR

19%

35%

NR

75.6% 21%

44%

NR

2%

66.1% 35.5%
21%

CIP

NR

NR

0.5%

7%

NR

NR

81.7% 37.8% 84.1% 74.4%

NR

NR

0

45.5%

47.9% 8.5% 38% 36.6%

NR 1.4%

42.1%

11.9% 10% 1.9%

40.6%

0.8% 18%

RIF LZD VAN

8%

7%

1.4%

NR

0.4% NR

NR

77%

72%

90% 23%

26%

7%

13%

NR

8%

5%

51.6%

NR

3.2% 22.6%

17%

13%

15% 13.5% 11.6%

0

0

25%

0

0

34.3% 28%

NR

3%

NR 1.6% 53.2%**

37.5%

OXA: Oxacillin, FOX: Cefoxitin, PEN: Penicillin, TET: Tetracycline, TMP/SXT: Trimethoprim/sulfamethoxazole, ERY: Erythromycin, CLN: Clindamycin, GEN: Gentamycin, CIP: Ciprofloxacin, RIF: Rifampicin, LZD: Linezolid, VAN: Vancomycin. *The resistance values reported are based on MRSA strains.
**Susceptibility to vancomycin was tested using disc diffusion method. NR: Not reported.

MRSA detection rate of 53.5% [24] while K’yanya et al. recently analyzed the
susceptibility profiles of 32 clinical isolates from four hospitals across Kenya
where higher susceptibilities to vancomycin, teicoplanin, tigecycline and linezolid were observed [25]. However, there were decreased susceptibilities to trimethoprim-sulfamethoxazole, tetracycline and ciprofloxacin and complete resistance to penicillin [25]. The authors applied whole genome sequencing (WGS)
to uncover both known and novel mechanisms of resistance which marked the
first Kenyan study employing genomic approaches to characterize the genetic
basis of resistance in clinical staphylococcal isolates [25].
Overall, the resistance ranges for seven most commonly tested drugs were: tetracycline (15.5% - 35.5%), trimethoprim-sulfamethoxazole (19% - 75.6%), erythromycin (11.9% - 81.7%), clindamycin (2% - 37.8%), gentamicin (1% - 84.1%)
and ciprofloxacin (7% - 74.4%). A major observation was the diminished efficacy of penicillin which varied from 66% in [21] to 100% in [25].

3.3. Molecular Characterization
The first report on staphylococcal cassette chromosome mec (SCCmec) characDOI: 10.4236/ojmm.2020.104018
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terization of MRSA was by Maina et al. who reported SCCmec II among MRSA
strains from SSTIs in Nairobi [14]. MRSA strains circulating in Thika level 5
hospital over a four-month period were classified as SCCmec III [19] as were
isolates from Aga Khan University Hospital and one public health facility in
Nairobi where SCCmec type-III [3A] predominated followed by SCCmec-IV
[2B] [26].
Omuse et al. assessed the detection frequencies of the Panton-Valentine leucocidin (pvl) gene among 45 carriage and 63 infective isolates from a private
health facility in Nairobi. Pvl was identified in 24.4% and 39.7% of carriage and
infective isolates respectively even though the differences did not attain statistical significance [27]. In the same study, there were significant differences in the
occurrence of pvl between skin and soft tissue infections isolates and isolates
from other sources [27]. Maina et al. reported pvl at a frequency of 20.3% among
MRSA isolates [14] while among carriage isolates recovered from inpatients at
Thika Level 5 Hospital it was 17% [19]. Kyany’a et al. recently applied whole genome sequencing (WGS) to identify multiple virulence genes and correlated
their occurrence with markers of severity of infection on a background of clonality where a handful showed significant associations [25].

Spa and MLST typing schemes have emerged as the most frequently used molecular methods for evaluating the evolutionary history of S. aureus [10]. The
first report on molecular characterization of MRSA was by Aiken et al. who employed DNA microarrays, spa and MLST typing. The study identified 28 unique

spa types (20 STs) in a collection of 86 S. aureus isolates where predominant
strains included ST22 (t223), ST8 (t064), ST239 (t037) and ST1290 (t131). All
MRSA strains belonged to ST239 (t037). Overall, the strains were clustered into
14 MLST clonal complexes which included CC1, CC5, CC8, CC15, CC22, CC30,
CC45, CC121 and CC239. Several spa types were represented by individual isolates which reflected the heterogeneity in the circulating MSSA strains. Five novel spa types were described and were all represented by MSSA strains. While two
novel spa types belonged to common STs (ST8 and 22), three corresponded to
STs that clustered as singletons [19].
An analysis of 93 isolates from a private and public hospital in Nairobi by
pulsed field gel electrophoresis (PFGE), spa and MLST identified 19 PFGE types
and 12 singletons which corresponded to 40 spa types (18 MRSA and 22 MSSA).
Global MRSA strain ST241 (t037) was identified as the predominant strain. Five
novel spa types including two MRSA strains (t13149/t13150) were also identified
[26]. In the same study, MLST CC5 which included STs 1, 5, 8 and 241 predominated [26].
Nyasinga et al. identified 22 spa types (21 STs) among isolates from three
counties (Nairobi, Kericho and Kisumu) where t355 (ST152) and t037 (ST241)
were the dominant MSSA and MRSA strains respectively. In addition, two novel
MSSA spa types were identified. Many spa/ ST types were represented by single
isolates and showed unique association with each region [9]. Kyany’a et al. utiDOI: 10.4236/ojmm.2020.104018
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lized WGS to characterize the strain diversity of clinical isolates from different
hospitals. Clonal classifications yielded 12 STs and 15 spa types that were clustered into 12 clonal complexes which included the global groups such as CC5,
CC8, CC22, CC152 [25].
BURP clustering included 191 isolates (59 spa types) after excluding 2 spa
types (t4198 and t10499) representing 3 isolates. Of these, 42 were MRSA while
152 were MSSA. t037 was the most common strain overall and consequently, the
most dominant MRSA strain, accounting for over 45% of all MRSA strains.
Other common strains included t064, t355, t223, t131 and t005. MRSA strains
were represented by 16 spa types while MSSA strains were represented by 41 spa
types. Four spa types contained both MRSA and MSSA strains. The algorithm
clustered isolates into 12 clusters and 19 singletons. However, four clusters including spa CC359, spa CC005, spa CC121 and spa CC021 accounted for 59%
(113/194) of all isolates. The four dominant clusters were composed of between
5 and 7 spa types each with seven of the remaining 8 clusters represented by two

spa types each (Figure 1).
In terms of regional distribution, 49 spa types were associated with individual
regions while only one spa type (t355) was present in all the four regions (Figure
2). Three of the four dominant clusters had representative spa types from three
regions while one had spa types from all four regions. There was marked heterogeneity among strains from Nairobi with overlaps with Thika and Kisumu and
to a lesser extent, Kericho. Fewer strains were uniquely associated with Kisumu
and Kericho regions even though this may be explained by lower isolate representation from the regions.

Figure 1. A based upon repeat pattern clustering analysis of spa types from different regions of Kenya. A total of 40 spa types were clustered into 12 clusters while 19 spa types
were classified as singletons. Two spa types (t4198 and t10499) were excluded in the analyses. Blue circles indicate the founders of each cluster.
DOI: 10.4236/ojmm.2020.104018
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Figure 2. A Venn diagram showing the distribution of reported spa types across four regions of Kenya. Different clusters and singletons are represented by different colors. Spa
types t021 and t3772 (not displayed) occurred in Nairobi and Kericho and Thika and Kisumu respectively. *Singletons; **spa types excluded from clustering analyses.

4. Discussion
4.1. Isolation of S. aureus
Examination of available data showed variable rates of clinical S. aureus detection in Kenya (2% - 52.6%) with a majority of studies skewed in favor of Nairobi.
Reported S. aureus isolation rates from other African countries have been inconsistent. In Eritrea, Garoy and others detected S. aureus in 63.1% of 130 specimens, mostly pus from two referral hospitals in Asmara [28]. S. aureus was detected in 28.7% of surgical site infections in Uganda [29] while in Tanzania, the
prevalence of S. aureus infections has been estimated to vary from 1% - 60%
[30]. The variable detection of S. aureus may be attributable to differences in
characteristics of specific study populations, the type of specimens collected,
type of healthcare facility and methodological differences. For instance, the bulk
of isolates were recovered from skin and soft tissue infection specimens whereas
blood cultures and other specimens had lower isolation frequencies. Further,
private health facilities had lower isolation frequencies compared to public
health facilities, probably due to effective implementation of infection prevention and control (IPC) programs and differences in the socio-demographic profiles of patients visiting such facilities compared to public ones. Some of these
factors have been attributed to variable isolation and AMR rates in other African
countries [5] [28].
Identification of S. aureus in most hospital laboratories in Kenya is based on
growth characteristics, gram stain and biochemical properties [22]. Specifically,
the coagulase test plays a critical role in distinguishing S. aureus from coagulase
DOI: 10.4236/ojmm.2020.104018
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negative staphylococci (CoNS). CoNS are more ubiquitous and may co-habit
with S. aureus on the skin and the anterior nares and thus their misidentification
as S. aureus would erroneously overestimate the burden of S. aureus in a given
setting [24]. Most CoNS are resistant to methicillin and other drugs and their
testing would exaggerate MRSA rates, further emphasizing the importance of
accurate identification.
In recent years, research institutes, major public and most private health facilities have adopted the use of automated bacterial identification platforms such as
the VITEK system [6] [22]. Despite their higher financial costs in comparison to
traditional identification, such platforms would increase the accuracy of identification. Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) is another technology whose utility in clinical diagnosis is beginning to be embraced albeit slowly due to its prohibitive costs in
resource-limited settings [31].
Many studies did not distinguish between community and hospital acquired
infections. However, Kyany’a et al. and Nyasinga et al. reported such delineation
where the bulk of skin and soft tissue infections caused by S. aureus were community acquired [9] [25]. The distinction between community and healthcare
associated infections is important especially with regards to MRSA strains which
display multidrug resistance. Community acquired MRSA (CA-MRSA) strains
are associated with possession of smaller mobile genetic elements (SCCmec) that
contain fewer resistance genes and hence display limited multidrug resistance
compared to healthcare associated MRSA strains (HA-MRSA) that contain larger elements with additional resistance determinants [3]. Further, CA-MRSA
strains have been suggested as being more virulent compared to HA-MRSA with
the possession of the Panton-Valentine leucocidin and acquisition of arginine
catabolic mobile element (ACME) [32]. However, clinically distinguishing
HA-MRSA from CA-MRSA is challenging as community acquired strains may
initiate infections in the healthcare setting while healthcare associated strains
may be transferred to the community where they can cause infections [8] [33].
Only two studies have evaluated S. aureus and MRSA carriage among HCWs.
One was performed in a public health facility where S. aureus detection was 34%
with an MRSA proportion of 59%. The other study was conducted in a private
hospital where S. aureus was identified in 18% of HCWs with none being MRSA.
A Cameroonian study reported a detection frequency of 40.6% among HCWs
and inpatients, which was higher than the highest reported rate from the two
Kenyan studies [34]. In the neighboring country of Tanzania, S. aureus was detected in 41.4% of HCWs in tertiary hospitals out of which 37.5% were MRSA
[35]. In Ethiopia, S. aureus detection among healthcare workers from two hospitals was 12% with an MRSA rate of 48.3% [36] while in Uganda, S. aureus detection and MRSA proportion were 28.8% and 46.4% respectively [37]. In contrast to African studies, a pooled MRSA detection of 1.8% has been reported
among HCWs in Europe and the USA [38]. MRSA carriage among HCWs poses
challenges in infection prevention and control prevention measures as colonized
DOI: 10.4236/ojmm.2020.104018
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individuals may act as reservoirs of infection for vulnerable patients. Transmission may occur even when colonized individuals are asymptomatic, though these
professionals likely act as vectors rather than direct transmitters [39]. Since
MRSA colonization is a risk factor for infection, infections may occur among
HCWs. Limited data exists on inpatient carriage of MRSA infections in Kenya as
only one study has previously explored this phenomenon thus revealing a gap
for future inquiry.
Given the skewed distribution of studies towards Nairobi and specifically the
Kenyatta National Hospital, it is difficult at present to establish a national estimate of the prevalence of staphylococcal infections. In many studies, data was
analyzed retrospectively and inevitably, there were gaps in clinical and socio-demographic data which may be useful in the estimation of risk factors for
infection or AMR spread. However, data from prospective, multicenter studies
covering other areas of the country are increasingly being reported [9] [25].
Further, the establishment of a national surveillance and reporting framework
will enable more accurate estimations of the extent of infections caused by S. aureus.

4.2. Antimicrobial Resistance Profiles of S. aureus
Reported MRSA detection varied from as low as 1% in blood isolates to as high
as 84.1% in skin and soft tissue infection isolates. Estimated MRSA detection
rates from other African countries include Tunisia (12% - 46%), Libya (31%),
South Africa (23% - 39%), Algeria (35% - 75%), Botswana (23% - 44%), Morocco (23%), Egypt (52% - 82%), Nigeria (9% - 41%), Madagascar (6%) and Ethiopia (55%) [5]. In Tanzania, MRSA prevalence has recently been reported at
33%, up from an earlier estimate of 16% [30]. A study from Eritrea reported an
MRSA proportion of 72% [28] while in Uganda, an MRSA rate of 31.5% among
surgical site infections was estimated [29]. Gonsu and others observed an MRSA
rate of 85% among Cameroonian HCWs and hospitalized patients which was
higher than the highest recorded rates in Kenya among HCWs (59.7%) and inpatients (7%) [34]. The variable rates of MRSA and resistance to other drugs has
been previously attributable to methodological variations, differences in antibiotic use, patient characteristics, variable HIV and TB burden in specific settings
and whether sampling is performed on rural or urban populations [5] [24].
Resistance to other drugs may be assessed in three categories: Complete,
moderate to high or negligible resistance. Penicillin was consistently reported as
having lost efficacy with most studies showing resistance rates between 92% 100%. Moderate to high resistance was reported in tetracycline (15.5% - 35.5%),
trimethoprim-sulfamethoxazole (19% - 75.6%); erythromycin (11.9% - 81.7%);
clindamycin (2% - 37.8%); gentamicin (1% - 84.1%), ciprofloxacin (7% - 74.4%)
and rifampicin (0.5% - 37.5%). In Tanzania, resistance against penicillin, erythromycin, trimethoprim-sulfamethoxazole and tetracycline has been observed at
85%, 49%, 38% and 28% respectively [30]. Garoy et al. recently observed resistance rates of 1%, 11% and 15.9% against gentamicin, erythromycin and vancoDOI: 10.4236/ojmm.2020.104018
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mycin [28]. However, the authors tested susceptibility to vancomycin using the
disc diffusion method which is not reliable in inferring resistance against the
drug. Besides penicillin whose efficacy has waned over the years, there seems to
be an increasing trend of reduced susceptibility to trimethoprim-sulfamethoxazole
(TMP-SXT), erythromycin and tetracycline. Resistance against these drugs is
primarily mediated by the dfr, erm and tet genes respectively. The high burden
of HIV/AIDS in Africa where TMP-SXT is widely used for patient management
has been cited as a potential driver of widespread resistance due to increased selection pressure [25]. Further, widespread veterinary use of antibiotics such as
tetracycline coupled with weak regulatory systems contributes to emergence of
resistance.
Mupirocin is an important agent for treatment of skin and soft tissue infections but also for topical decolonization of patients and healthcare workers.
However, mupirocin resistant S. aureus (MupRSA) strains are increasingly being
reported [40]. Resistance may be mediated by point mutations or horizontal acquisition of plasmids carrying resistance genes such as mupA and mupB [41].
Mupirocin resistance in Kenya as reported by the few studies ranged from 0% 18% in comparison with the continental pooled estimate of 14% (0% - 49.6%)
[40]. High level mupirocin resistance has recently been observed among carriage
strains in Uganda [42].
Last line treatments such as vancomycin, linezolid, daptomycin and teicoplanin had negligible to no resistance (<5%). At the continental level comparable
rates have been reported with MRSA strains showing greater resistance [5]. Linezolid, an oxazolidinone that acts by binding to domain V of the 23S ribosomal
sub-unit to inhibit functional ribosomal complex assembly and daptomycin, a
lipopeptide that acts on the cell membrane in a calcium ion dependent manner
are highly effective against MRSA strains. However, resistance against linezolid,
mediated by point mutations and the plasmid-borne chloramphenicol florfenicol
resistance (cfr) gene has already been observed in other settings [43]. The cfr
gene has also been implicated in phenotypic expression of resistance against other
classes such as lincosamides and phenicols [44]. Resistance against daptomycin,
mediated by a variety of mechanisms is increasingly being recognized in S. aureus
[45]. Initial observation of resistance coupled with the expiry of patents for the two
drugs and their impending decreased costs and greater availability calls for vigilance through constant surveillance for emerging resistant strains as prolonged use
has been suggested as a key driver of linezolid resistance. The threat of widespread
resistance is compounded by the occurrence of linezolid and high level daptomycin resistance among coagulase negative Staphylococci [44] which may act as a
pool of resistance genes for the more pathogenic S. aureus [46].
There is a need for uniformity in interpretation and reporting of isolate susceptibilities to different drug classes in accordance with international guidelines
such as the CLSI. For example, there were instances where susceptibility to vancomycin was tested using disc diffusion method and was not verified by other
methods such as minimum inhibitory concentration (MIC) determination or moDOI: 10.4236/ojmm.2020.104018
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lecular detection of vancomycin resistance genes. Incorporation of molecular
methods such as PCR and whole genome sequencing in routine AMR surveillance would reveal existing and novel mechanisms of resistance. Further, characterization of resistance among CoNS would uncover potential transmission
pathways of existing and new resistance mechanisms.

4.3. Molecular Characterization of Staphylococcus aureus
The Panton-Valentine leucocidin, a bi-component exotoxin encoded by LukSand LukF-PV genes that acts by forming pores on target immune cells was reported at frequencies of between 17% and 33%. A Gambian study established a
PVL prevalence of 61.4% among bacteremia and SSTI isolates [47]. At the continental level, PVL prevalence has varied from 0.3% - 100% [8]. The role of PVL
in mediating severity of infection has been controversial with some studies linking it to syndromes such as S. aureus mediated pyomyositis and necrotizing
pneumonia [48] but not others [49]. The prevalence of the toxin seems to be significantly higher in Africa compared to other regions and investigations on its
higher prevalence and potential role in disease pathogenesis are invited.
BURP clustering revealed the presence of four major clusters: CC359, CC005,
CC121 and CC021. Nairobi region showed marked heterogeneity with representatives from different clusters as well as singletons. Further, strains from
Nairobi showed considerable overlap with strains from other regions (Figure 2).
This heterogeneity may be explained by the population size of Nairobi city
county which is the most populous in the country coupled with increased human mobility into and out of the city. Overall, spa types t037, t064, t355 and t223
were dominant. There seems to be limited heterogeneity among MRSA strains
with ST239/241 (t037) being the dominant strain. In Uganda, t645, t4353, t355,
t037 and t064 are the most common with t645 and t4353 appearing less frequently in Kenya [42]. Spa types t037 has been associated with HA-MRSA
strains while t064 has been linked to CA-MRSA infections in Uganda [42]. Spa
types t042 and t044 have been observed in Egypt and Algeria and were not reported in Kenya [8] whereas in Ghana, t355, t084, t10519 and t008 have been the
preponderant strains [50]. Contrary to Kenya where ST239 (t037), ST152 (t355)
and ST8 (t064) are dominant, ST88 which is the quintessential African strain has
been suggested as the predominant circulating strain in Tanzania [30].
From the collection evaluated, CA-MRSA strain USA3OO (ST 8/CC8;
t008/spa CC008) was not observed. However, t002 (ST5) which is associated
with HA-MRSA infections (USA1OO) was observed in Nairobi, Thika and Kisumu though none of the isolates were MRSA. The observation of pandemic
ST239/241(t037) strain in circulation calls for increased surveillance to track
transmission of MRSA strains in Kenya. Further, molecular characterization is
essential to unravel the changing epidemiology of the pathogen where increased
human travel across borders and other factors may lead to displacement of existing clones by introduction of fitter ones as happened in the United Kingdom
where EMRSA-15 (ST22) and EMRSA-16 (ST36) displaced other MRSA strains
DOI: 10.4236/ojmm.2020.104018
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to establish their dominance [51].

5. Concluding Remarks
Currently available data points to S. aureus variable detection and AMR rates in
Kenya. While penicillin has lost its efficacy, there are hints of decreasing effectiveness for commonly prescribed antimicrobial classes. Many of the last line
and recent treatments remain largely effective. The population structure of S.
aureus in Kenya is heterogeneous with the presence of major global lineages in
circulation.
Presently, it is difficult to establish the clinical and economic burden of MRSA
infections in Kenya due to factors such as weak national AMR surveillance and
reporting mechanisms, self-medication and poor regulation of antimicrobial use.
Further, inadequate diagnostic microbiology infrastructure in many health facilities coupled with empirical treatments are major obstacles [52]. In light of this,
the Kenya government enacted the national policy for prevention and containment of AMR which recognizes the threat of AMR and seeks to initiate and implement AMR prevention and control strategies in line with the global action
plan (GAP) on tackling AMR from a One Health perspective.
Antimicrobial resistance remains a One Health challenge that warrants interdisciplinary efforts at the human-animal-environment interface. However, there
remains limited data on the prevalence of drug resistant staphylococcal infections among animal populations and environmental settings in Kenya, an area
where collaborative efforts are imperative.
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